Search results
Results from the WOW.Com Content Network
The stock’s rock-solid dividend and its growth potential from a number of positive wins suggest GSK stock will still climb higher. GlaxoSmithKline Is More Than Just a 5% Dividend Income Play ...
The London-listed drugmaker said it now expects a rise of 8% to 10% in annual adjusted earnings per share, up from the 6%-9% growth previously forecast. It also expects its 2024 sales to rise in ...
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see...
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. ... including dividends, or 2.3% on an annualised ...
British drugmaker GSK cut its forecast for 2024 vaccine sales on Wednesday after quarterly revenue from its blockbuster shingles and respiratory syncytial virus (RSV) jabs missed expectations ...
GSK now expects annual adjusted earnings per share to rise between 17% and 20%, excluding the effect of currency swings, up from 14% to 17% growth previously forecast.
-GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and ...